Literature DB >> 25016223

Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation.

Bertram Bengsch1, Bianca Martin1, Robert Thimme2.   

Abstract

BACKGROUND & AIMS: The upregulation of several inhibitory signalling pathways by exhausted HBV-specific CD8+ T cells in chronic infection is thought to contribute to viral persistence. Blockade of inhibitory receptors to reinvigorate exhausted T cell function is a promising novel therapeutic approach. However, little information is available regarding the relative contribution of individual inhibitory pathways to HBV-specific CD8+ T cell failure and the impact of inhibitory receptor blockade on restoration of T cell function in chronic HBV.
METHODS: 98 HLA-A2+ chronically infected patients were analysed ex vivo for HBV-specific CD8+ T cell responses, the expression of multiple inhibitory receptors and T cell differentiation markers. The effects of inhibitory receptor blockade targeting PD-1, 2B4, Tim-3, CTLA-4, and BTLA were assessed in vitro.
RESULTS: In our cohort, ex vivo HBV-specific CD8+ T cell responses were identified preferentially in HBeAg patients with low ALT and low viral load (inactive carriers). We observed a clear hierarchy of inhibitory receptor expression dominated by PD-1. The response to inhibitory receptor blockade was heterogeneous. Compared to the blockade of other inhibitory receptors, blockade of the PD-1 pathway resulted in the strongest increase in function. Of note, a positive effect of PD-1 blockade was linked to intermediate T cell differentiation.
CONCLUSIONS: Despite the expression of multiple inhibitory receptors by HBV-specific CD8+ T cells, expression and response to blockade was dominated by PD-1. However, PD-1 expression did not predict response to blockade. Rather, response to blockade was associated with intermediate T cell differentiation. These findings have important implications for our understanding of inhibitory receptor blockade as a novel therapeutic strategy.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  HBV; Inactive carrier; Inhibitory receptors; PD-1; T cell differentiation; T cell exhaustion; Virus-specific CD8+ T cells

Mesh:

Substances:

Year:  2014        PMID: 25016223     DOI: 10.1016/j.jhep.2014.07.005

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  86 in total

Review 1.  Present and future therapies of hepatitis B: From discovery to cure.

Authors:  T Jake Liang; Timothy M Block; Brian J McMahon; Marc G Ghany; Stephan Urban; Ju-Tao Guo; Stephen Locarnini; Fabien Zoulim; Kyong-Mi Chang; Anna S Lok
Journal:  Hepatology       Date:  2015-10-27       Impact factor: 17.425

2.  PD-1/PD-L1 signal pathway participates in HCV F protein-induced T cell dysfunction in chronic HCV infection.

Authors:  Wen Xiao; Long Feng Jiang; Xiao Zhao Deng; Dan Yan Zhu; Jia Ping Pei; Mao Lei Xu; Bing Jun Li; Chang Jun Wang; Jing Hai Zhang; Qi Zhang; Zhen Xian Zhou; Wei Liang Ding; Xiao Dong Xu; Ming Yue
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

3.  The characteristics of NK cells in Schistosoma japonicum-infected mouse spleens.

Authors:  Lu Li; Hefei Cha; Xiuxue Yu; Hongyan Xie; Changyou Wu; Nuo Dong; Jun Huang
Journal:  Parasitol Res       Date:  2015-08-29       Impact factor: 2.289

Review 4.  Immune checkpoint inhibitors for hepatocellular carcinoma.

Authors:  Christopher E Jensen; Arturo Loaiza-Bonilla; Paula A Bonilla-Reyes
Journal:  Hepat Oncol       Date:  2016-06-27

Review 5.  Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection.

Authors:  Barbara Rehermann; Robert Thimme
Journal:  Gastroenterology       Date:  2018-09-26       Impact factor: 22.682

6.  PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection.

Authors:  S Klein; D Ghersi; M P Manns; I Prinz; M Cornberg; A R M Kraft
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

Review 7.  Mechanisms of Hepatitis B Virus Persistence.

Authors:  Kuen-Nan Tsai; Cheng-Fu Kuo; Jing-Hsiung James Ou
Journal:  Trends Microbiol       Date:  2017-08-16       Impact factor: 17.079

Review 8.  Hepatitis B: Current Status of Therapy and Future Therapies.

Authors:  Elias Spyrou; Coleman I Smith; Marc G Ghany
Journal:  Gastroenterol Clin North Am       Date:  2020-03-29       Impact factor: 3.806

9.  Deep immune profiling by mass cytometry links human T and NK cell differentiation and cytotoxic molecule expression patterns.

Authors:  Bertram Bengsch; Takuya Ohtani; Ramin Sedaghat Herati; Niels Bovenschen; Kyong-Mi Chang; E John Wherry
Journal:  J Immunol Methods       Date:  2017-03-19       Impact factor: 2.303

Review 10.  Advances in therapeutics for chronic hepatitis B.

Authors:  Ninghan Yang; Antonio Bertoletti
Journal:  Hepatol Int       Date:  2015-09-12       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.